{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:56:08Z","timestamp":1785560168748,"version":"3.56.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.urology.2025.01.070","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T16:13:42Z","timestamp":1738599222000},"page":"1-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Implementing and Optimizing Universal Germline Genetic Testing for Patients With Prostate Cancer in Clinical Practice"],"prefix":"10.1016","volume":"199","author":[{"given":"Neal","family":"Shore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Barata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Hafron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Channing","family":"Paller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Wise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Ventii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Samadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Arangua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya N.","family":"Werahera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Lorentz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2025.01.070_bib1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urology.2025.01.070_bib2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/pros.23739","article-title":"Germline genetic testing for inherited prostate cancer in practice: implications for genetic testing, precision therapy, and cascade testing","volume":"79","author":"Giri","year":"2019","journal-title":"Prostate"},{"key":"10.1016\/j.urology.2025.01.070_bib3","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jama.2017.11137","article-title":"Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing","volume":"318","author":"Mandelker","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.urology.2025.01.070_bib4","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/jamaoncol.2018.6760","article-title":"Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines","volume":"5","author":"Nicolosi","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urology.2025.01.070_bib5","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-Repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2025.01.070_bib6","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/jamaoncol.2020.6252","article-title":"Comparison of Universal Genetic Testing vs guideline-directed targeted testing for patients with hereditary cancer syndrome","volume":"7","author":"Samadder","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urology.2025.01.070_bib7","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.euo.2023.07.008","article-title":"Efficacy of National Comprehensive Cancer Network Guidelines in identifying pathogenic germline variants among unselected patients with prostate cancer: the PROCLAIM Trial","volume":"6","author":"Shore","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urology.2025.01.070_bib8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41436-019-0596-9","article-title":"Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the prospective lynch syndrome database","volume":"22","author":"Dominguez-Valentin","year":"2020","journal-title":"Genet Med"},{"key":"10.1016\/j.urology.2025.01.070_bib9","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1136\/gutjnl-2017-314057","article-title":"Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database","volume":"67","author":"Moller","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.urology.2025.01.070_bib10","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.20034","article-title":"Early prostate cancer deaths among men with higher vs lower genetic risk","volume":"7","author":"Plym","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.urology.2025.01.070_bib11","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.eururo.2019.08.019","article-title":"Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers","volume":"76","author":"Page","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2025.01.070_bib12","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and olaparib for metastatic castration-resistant prostate cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.urology.2025.01.070_bib13","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer","volume":"41","author":"Chi","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2025.01.070_bib14","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.urology.2025.01.070_bib15","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","article-title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","volume":"33","author":"Maio","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urology.2025.01.070_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2025.01.070_bib17","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.urology.2025.01.070_bib18","article-title":"Genetic testing utilization: discrepancies between somatic and germline results in patients with cancer reviewed at the UW health precision medicine molecular tumor board","volume":"8","author":"Horn","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.urology.2025.01.070_bib19","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.19452","article-title":"Yield and utility of germline testing following tumor sequencing in patients with cancer","volume":"3","author":"Lincoln","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.urology.2025.01.070_bib20","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1016\/j.amepre.2018.05.028","article-title":"Attitudes toward genomic testing and prostate cancer research among black men","volume":"55","author":"Rogers","year":"2018","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.urology.2025.01.070_bib21","article-title":"Universal germline genetic testing for hereditary cancer syndromes in patients with solid tumor cancer","volume":"6","author":"Esplin","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.urology.2025.01.070_bib22","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.ejso.2017.12.003","article-title":"The new Epstein gleason score classification significantly reduces upgrading in prostate cancer patients","volume":"44","author":"De Nunzio","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.urology.2025.01.070_bib23","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00261-018-1751-5","article-title":"Assessment of PI-RADS v2 categories >\/= 3 for diagnosis of clinically significant prostate cancer","volume":"44","author":"Patel","year":"2019","journal-title":"Abdom Radiol (NY)"},{"key":"10.1016\/j.urology.2025.01.070_bib24","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/pros.24480","article-title":"Utilization of genetic testing in men with advanced prostate cancer","volume":"83","author":"Aguiar","year":"2023","journal-title":"Prostate"},{"key":"10.1016\/j.urology.2025.01.070_bib25","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.eururo.2018.09.021","article-title":"Germline mutations in ATM and BRCA1\/2 are associated with grade reclassification in men on active surveillance for prostate cancer","volume":"75","author":"Carter","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2025.01.070_bib26","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/pros.23535","article-title":"Understanding of multigene test results among males undergoing germline testing for inherited prostate cancer: Implications for genetic counseling","volume":"78","author":"Giri","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.urology.2025.01.070_bib27","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41525-024-00412-0","article-title":"Strategies to improve implementation of cascade testing in hereditary cancer syndromes: a systematic review","volume":"9","author":"Chiang","year":"2024","journal-title":"NPJ Genom Med"},{"key":"10.1016\/j.urology.2025.01.070_bib28","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.euf.2022.03.018","article-title":"What is a variant of uncertain significance in genetic testing?","volume":"8","author":"Nicolosi","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urology.2025.01.070_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/s41391-024-00901-4","article-title":"Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2)","author":"Armstrong","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.urology.2025.01.070_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41391-024-00887-z","article-title":"Therapeutic implications of homologous repair deficiency testing in patients with prostate cancer (Part 2 of 2)","author":"Serritella","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429525001141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429525001141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T08:18:12Z","timestamp":1746519492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429525001141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":30,"alternative-id":["S0090429525001141"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2025.01.070","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Implementing and Optimizing Universal Germline Genetic Testing for Patients With Prostate Cancer in Clinical Practice","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2025.01.070","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}